Download PDF
Thromb Haemost 1968; 19(01/02): 117-128
DOI: 10.1055/s-0038-1651188
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Some Complexities of Multiple Inhibitor Interactions in Fibrinolytic Systems

R. E Maxwell
1   Department of Chemistry, Parke-Davis Research Laboratories, Ann Arbor, Michigan 48106
,
J. W Nawrocki
1   Department of Chemistry, Parke-Davis Research Laboratories, Ann Arbor, Michigan 48106
,
Violet S. Nickel
1   Department of Chemistry, Parke-Davis Research Laboratories, Ann Arbor, Michigan 48106
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

    Permissions and Reprints

Summary

Human or canine fibrin polymers which are structurally altered by the combined action of plasmin and EACA show an increased resistance to digestion by trypsin, but not to digestion by chymotrypsin. These observations support the concept that EACA inhibition of fibrinolysis is to a variable extent a function of structural changes in the substrate, and that the changes may be related to the susceptibility of lysyl- and arginyl-sites attacked by plasmin and trypsin, but not by chymotrypsin.

In plasma, the fibrin modification reactions mediated by plasmin + EACA are analogous to those in purified systems, with quantitative differences resulting from the presence of other inhibitors, and perhaps from earlier gelation of the developing polymers.

This complexity of the action of EACA must be taken into account in comparing its effects with those of other inhibitors, which also have variable and non-linear effects related to prevention of autodigestion of plasmin, antagonistic or potentiative combinations of inhibitors, and interference with substrate conversion.

 

  • References

  • 1 Donaldson V.H. Activation of Partially Purified Plasminogen in the Presence of E-Amino-caproic Acid. J. Lab. clin. Med. 1964; 63: 213
    PubMedGoogle Scholar
  • 2 Alkjaersig N, Fletcher A.P, Sherry S. E-Aminocaproic Acid: An Inhibitor of Plasminogen Activation. J. biol. Chem. 1959; 234: 832
    PubMedGoogle Scholar
  • 3 Maxwell R.E, Lewandowski V, Nickel V.S. Effects of Some Amino Acids on the Inhibition of Plasmin by Aptiplasmin. Biochim. biophys. Acta (Amst.) 1965; 99: 342
    CrossrefPubMedGoogle Scholar
  • 4 Egeblad K. Effects of ɛ-Aminocaproic Acid on Fibrin Clot Lysis. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; 15: 173
    PubMedGoogle Scholar
  • 5 Maxwell R.E, Lewandowski V, Nickel V.S. Enhancement of Fibrinolysis and Antagonism of Antiplasmin by Reversible Plasmin Inhibitors. Life Sci. 1965; 4: 45
    CrossrefPubMedGoogle Scholar
  • 6 Ablondi F.B, Hagan J.J, Philips M, De Renzo E.C. Inhibition of Plasmin Trypsin, and the Streptokinase-Activated Fibrinolytic System by E-Aminocaproic Acid. Arch. Biochem. 1959; 82: 153
    CrossrefPubMedGoogle Scholar
  • 7 Celander D.R, Naschke M.D, Guest M.M. The Effect of E-Aminocaproic Acid on Fibrino-lysin and on Activators of Profibrinolysin. Texas Rep. Biol. Med. 1961; 19: 50
    PubMedGoogle Scholar
  • 8 Blix S. The Effectiveness of Activators in Clot Lysis, with Special Reference to Fibrinolytic Therapy. Acta med. scand. 172, Suppl. 1962; 386: 1
    PubMedGoogle Scholar
  • 9 Ambrus, C.M., J.L. Ambrus, H.B. Lassman, I.B. Mink: Studies on the Mechanism of Action of Inhibitors of the Fibrinolysis System. Ann. N. Y. Acad. Sci.(In Press.).
    PubMed
  • 10 Maxwell R.E, Allen D. Interactions of E-Aminocaproic Acid with the Thrombin Clotting and Fibrinolytic Systems. Nature (Lond.) 1966; 209: 211
    CrossrefPubMedGoogle Scholar
  • 11 Maxwell R.E. Enhancement or Inhibition of Fibrinolysis by Reversible Plasmin Inhibitors. Fed. Proc. 1966; 25: 498
    PubMedGoogle Scholar
  • 12 Maxwell R.E, Lewandowski V, Nickel V.S, Nawrocki J.W. Substrate Modification and the Mechanism of Potentiation of Plasmin Inhibition by ω-Amino Acids. Abstrs., Fifteenth Annual Symposium on Blood. Thrombos. Diathes. haemorrh. (Stuttg.) 1967; 18: 299
    PubMedGoogle Scholar
  • 13 Maxwell R.E, Lewandowski V, Allen D. Fibrinolytic Assay Based on Turbidity of Polystyrene Particles Released from the Clot. Analyt. Biochem. 1966; 16: 53
    CrossrefPubMedGoogle Scholar
  • 14 Loomis E.C, Ryder A, George C. Fibrinolysin and Antifibrinolysin: Biochemical Concentration of Antifibriolysin. Arch. Biochem. 1949; 20: 444
    PubMedGoogle Scholar
  • 15 Maxwell B.E, Nickel V.S, Lewandowshi V. Preparations of Plasminogen-Deficient Fibrinogen and Thrombin. Biochem. biophys. Res. Commun. 1962; 7: 50
    CrossrefPubMedGoogle Scholar
  • 16 Straughn III W, Wagner R.H. A Simple Method for Preparing Fibrinogen. Thrombos. Diathes. haemorrh. (Stuttg.) 1966; 16: 198
    PubMedGoogle Scholar
  • 17 Maxwell R.E, Lewandowski V. Modified Fibrinolytic Technique for Analysis of the Plasmin System. Analyt. Biochem. 1962; 4: 407
    CrossrefPubMedGoogle Scholar
  • 18 Troll W, Sherry S, Wachman J. The Action of Plasmin on Synthetic Substrates. J. biol. Chem. 1954; 205: 85
    PubMedGoogle Scholar
  • 19 Scheraga H.A. M. Laskowski, Jr.: The Fibrinogen-Fibrin Conversion. Advanc. Protein Chem. 1957; 12: 1
    PubMedGoogle Scholar
  • 20 Endres G.F, Scheraga H.A. Equilibria in the Fibrinogen-Fibrin Conversion. VII. On the Mechanism of the Reversible Polymerization of Fibrin Monomer. Biochemistry (Wash.) 1966; 5: 1568
    PubMedGoogle Scholar
  • 21 Fletcher A.P, Alkjaersig N, Fisher S, Sherry S. The Proteolysis of Fibrinogen by Plasmin: The Identification of Thrombin-Clottable Fibrinogen Derivatives Which Polymerize Abnormally. J. Lab. clin. Med. 1966; 68: 780
    PubMedGoogle Scholar
  • 22 Hirsh J, Fletcher A.P, Sherry S. Effect of Fibrin and Fibrinogen Proteolysis Products on Clot Physical Properties. Amer. J. Physiol. 1965; 209: 415
    PubMedGoogle Scholar
  • 23 Pechet L, Alexander B. The Effect of Certain Proteolytic Enzymes on the Thrombin-Fibrinogen Interaction. Biochemistry (Wash.). 1962; 1: 875
    PubMedGoogle Scholar
  • 24 Triantaphyllopoulos D.C, Triantaphyllopoulos E. Evidence of Antithrombic Activity of the Anticoagulant Fraction of Incubated Fibrinogen. Brit. J. Haemat. 1966; 12: 145
    CrossrefPubMedGoogle Scholar
  • 25 Ferry J.D, Shulman S. The Conversion of Fibrinogen to Fibrin. I. Influence of Hydroxyl Compounds on Clotting Time and Clot Opacity. J. Amer. chem. Soc. 1949; 71: 3198
    PubMedGoogle Scholar
  • 26 Von Korff B.W, Bronfenbrenner A. A Difference in Bovine and Human Fibrinopeptides with Respect to the Occurrence of Tyrosine-O-Sulfate. J. Amer. chem. Soc. 1958; 80: 5575
    PubMedGoogle Scholar
  • 27 Blombäck B, Dolittle B.F. Amino Acid Sequence Studies on Fibrinoeptides from Several Species. Acta chem. scand. 1963; 17: 1819
    CrossrefPubMedGoogle Scholar
  • 28 Blombäck B, Blombäck M, Edman P, Kessel B. Human Fibrinopeptides. Isolation, Characterization and Structure. Biochim. biophys. Acta (Amst.) 1966; 115: 371
    CrossrefPubMedGoogle Scholar
  • 29 Mills D.A, Coyne R, Pollara B, Von Korff B.W. The Action of Plasmin on Fibrinogen and Fibrin I. Changes in the N-Terminal Residues. Biochim. biophys. Acta (Amst.) 1964; 86: 527
    PubMedGoogle Scholar
  • 30 Bosenfeld L. Clot Opacity and the Thrombin-Plasma Reaction. Arch. Biochem. 1965; 111: 660
    CrossrefPubMedGoogle Scholar
  • 31 Ferry J.D, Morrison P.R. Preparation and Properties of Serum and Plasma Proteins. VIII. The Conversion of Human Fibrinogen to Fibrin Under Various Conditions. J. Amer. chem. Soc. 1947; 69: 388
    PubMedGoogle Scholar
  • 32 Chandrasekhar N, Osbahr A, Kali K. The Mode of Action of the Laki-Lorand Factor in the Clotting of Fibrinogen. Biochem. biophys. Res. Commun. 1964; 15: 182
    CrossrefPubMedGoogle Scholar
  • 33 Lorand L, Doolittle R.F, Konishi K, Biggs S.K. A New Class of Blood Coagulation Inhibitors. Arch. Biochem. 1963; 102: 171
    CrossrefPubMedGoogle Scholar
  • 34 Abilgaard U. N-Terminal Analysis During Coagulation of Purified Human Fibrinogen. Fraction I, and Plasma. Scand. J. clin. Lab. Invest. 1965; 17: 529
    PubMedGoogle Scholar
  • 35 Bimon A, Shamash Y, Shapiro B. The Plasmin Inhibitor of Human Plasma. IV. Its Action on Plasmin, Trypsin. Chymotrypsin, and Thrombin. J. biol. Chem. 1966; 241: 5102
    PubMedGoogle Scholar
  • 36 Webb J.L. Enzyme Metabolic Inhibitors Vol. Academic Press I. N.Y. 1963
    PubMed
  • 37 Bose I.A. Mechanisms of Enzyme Action. Ann. Rev. Biochem. 1966; 35: 23
    CrossrefPubMedGoogle Scholar
  • 38 Green N.M. Competition Among Trypsin Inhibitors. J. biol. Chem. 1953; 205: 535
    PubMedGoogle Scholar
  • 39 Muramatu M, Onishi T, Makino S, Fujii S, Yamamura Y. Inhibition of Fibrinolytic Activity of Plasmin by Various Synthetic Inhibitors. J. Biochem. (Tokyo) 1965; 57: 450
    CrossrefPubMedGoogle Scholar
  • 40 Sjoerdsma A, Nilsson I.M. Aliphatic Amino Compounds as Inhibitors of Plasminogen Activation. Proc. Soc. exp. Biol. (N. Y.) 1960; 103: 533
    CrossrefPubMedGoogle Scholar